Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $13.75 down -1.93% from its previous closing price of $14.02. In other words, the price has decreased by -$1.93 from its previous closing price. On the day, 1.61 million shares were traded. ARQT stock price reached its highest trading level at $14.31 during the session, while it also had its lowest trading level at $13.7.
Ratios:
For a deeper understanding of Arcutis Biotherapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.37 and its Current Ratio is at 3.55. In the meantime, Its Debt-to-Equity ratio is 0.78 whereas as Long-Term Debt/Eq ratio is at 0.77.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.
Mizuho Upgraded its Neutral to Buy on January 03, 2024, whereas the target price for the stock was revised from $4 to $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 01 ’25 when Welgus Howard G. bought 9,208 shares for $13.84 per share.
Welgus Howard G. sold 10,139 shares of ARQT for $135,574 on Jun 18 ’25. The Director now owns 109,414 shares after completing the transaction at $13.37 per share. On Jun 18 ’25, another insider, Welgus Howard G., who serves as the Director of the company, bought 10,139 shares for $13.37 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1671202560 and an Enterprise Value of 1583920128. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.70 while its Price-to-Book (P/B) ratio in mrq is 11.48. Its current Enterprise Value per Revenue stands at 7.443 whereas that against EBITDA is -13.663.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.77, which has changed by 0.43229163 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $17.75, while it has fallen to a 52-week low of $7.86. The 50-Day Moving Average of the stock is -1.81%, while the 200-Day Moving Average is calculated to be 7.51%.
Shares Statistics:
For the past three months, ARQT has traded an average of 2.19M shares per day and 2118410 over the past ten days. A total of 119.14M shares are outstanding, with a floating share count of 104.80M. Insiders hold about 12.08% of the company’s shares, while institutions hold 98.77% stake in the company. Shares short for ARQT as of 1749772800 were 18643341 with a Short Ratio of 8.50, compared to 1747267200 on 16035003. Therefore, it implies a Short% of Shares Outstanding of 18643341 and a Short% of Float of 19.34.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
